CureVac IPO. Beating Rivals to Secure a COVID-19 Vaccine Based on MRNA Technology
German global clinical-stage biotech company and coronavirus vaccine developer CureVac set terms for $200M+ IPO (~13.3 million shares) at a...
506 Views
Lonza: A Bellwether Biopharma Focused CDMO | At Inflection Point, To Benefit from Ongoing Capex
Over the next few weeks/months, we will be initiating coverage on a few key players in the Global CDMO space, where we see interesting growth...
443 Views
U.S. Equity Strategy: Several Indicators Suggest a Pullback Likely
Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight...
440 Views
Moderna Inc (MRNA US) - Insights About the Performance in Front of Omicron
This article analyzed the revenue forecast of Moderna according to the various scenarios of Omicron depending on its severity. We also analyzed...
306 Views